1. Neville A.M., O’Hare M.J. The human adrenal cortex Springer-Verlag. Berlin – Heidelberg – New-York 1982; 354.
2. Young WF. Jr Primary aldosteronism. In: Secondary Hypertension. Ed. G.A.Mansoor. Humana Press, Totowa, New Jersey, 2004; 119–37.
3. Шхвацабая И.К., Чихладзе Н.М. Гиперальдостеронизм и артериальная гипертония. М.: Медицина, 1984; 136.
4. Haab F, Duclos JM, Guyenne T et al. Renin secreting tumors diagnosis, conservative surgical approach and long-term results. J Urol 1995; 153: 1781–4.
5. Шхвацабая И.К., Устинова С.Е., Казеев К.Н. и др. Ренинпродуцирующая опухоль почки и артериальная гипертония. Кардиология. 1985; 25 (7): 114–7.
6. Baer L, Sommers SC, Krakoff LR et al. Pseudoprimary aldosteronism: an entity distinct from true primary aldosteronism. Circ Res 1970; 27 (Suppl. 1): 203–20.
7. Ironi I, Kater CE, Biglieri EG, Shackleton CH. Correctable subsets of primary aldosteronism: primary adrenal hyperplasia and renin responsive adenoma. Am J Hypertens 1990; 3: 576–82.
8. Stowasser M, Gartside MG, Gordon RD. A PCR-based method of sсreening individuals of all ages, from neonates to the elderly, for familial hyperaldosteronism type I. Aust N.Z. j. 1997; 27: 685–90.
9. Lifton RP, Dluhy RG, Powers M et al. A chimaeric 11β-hydroxylase/aldosterone syntase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355: 262–5.
10. Чихладзе Н.М., Арабидзе Г.Г., Stowasser M и др. Выявление химерного гена 11β-гидроксилазы/альдостеронсинтазы у больных с глюкокортикоидзависимой семейной формой гиперальдостеронизма. Артер. гипертен. 1999; 5 (1): 57–8.
11. Kaplan N.M. Primary aldosteronism. Kaplan's clinical hypertension. 8-th eds. Lippincott Williams & Wilkins, 2002; 455–79.
12. Чихладзе Н.М., Бронштейн М.Э., Казеев К.Н., Арабидзе Г.Г. Кризовое течение артериальной гипертонии у больных с первичным гиперальдостеронизмом. Кардиология. 1989; 11: 95–9.
13. Gordon RD, Stowasser M, Tunny TJ et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315–8.
14. Ferris JB, Beevers DG, Brown JJ. Low-renin ("primary") hyperaldosteronism. Am Heart J 1978; 5: 641–58.
15. Gordon RD, Hamlet SM, Tunny T, Klemm S. Aldosterone-producing adenomas responsive to angiotensin pose problem in diagnosis. Clin Exp Pharmacol Physiol 1987; 14: 175–9.
16. Stowasser M, Gartside MG, Gordon RD. A PCR-based method of sсreening individuals of all ages, from neonates to the elderly, for familial hyperaldosteronism type I. Aust N.Z. j. 1997; 27: 685–90.
17. Bravo E.H. Medical Management of Primary Aldosteronism. Secondary Hypertension. Ed. G.A.Mansoor. Humana Press. Totowa, New Jersey, 2004; 139–48.
18. Tunder JW. Eplerenone, a new mineralocorticoid antagonist: in vitro and in vivo studies. Curr Opion Endocrinol Diabetes 2000; 7: 138–42.
19. Lim PO, Young WF, MacDonald IM. A review of the medical treatment of primary aldosteronism. J Hypertens 2001; 19: 353–61.
Авторы
Н.М.Чихладзе, И.Е.Чазова
Российский кардиологический научно-производственный комплекс Росздрава, Москва